Pavlos Msaouel
机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0001-6505-8308
发表论文 562 篇 · 总被引 6696 次 · h-index 43
代表论文
- Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity (2026 · Clinical Cancer Research)
- Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis (2026 · Cancer Immunology Research)
- Supplementary Table S8 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma (2026)
- Supplementary Appendix S1 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma (2026)
- Supplementary Table S3 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma (2026)
- Supplementary Figure S4 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma (2026)